Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 USD | +5.77% | +2.80% | -77.92% |
Apr. 01 | UBS Trims CareMax Price Target to $6.40 From $7, Maintains Neutral Rating | MT |
Mar. 18 | Transcript : CareMax, Inc., Q4 2023 Earnings Call, Mar 18, 2024 |
Valuation
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Capitalization 1 | 280.3 | 668.7 | 404.8 | 55.97 | 12.55 | - | - |
Enterprise Value (EV) 1 | 280.3 | 738 | 594.1 | 376.3 | 438.3 | 568.4 | 12.55 |
P/E ratio | - | -59.1 x | -8.69 x | -0.08 x | -0.11 x | -0.17 x | -0.3 x |
Yield | - | - | - | - | - | - | - |
Capitalization / Revenue | 2.33 x | 1.66 x | 0.64 x | 0.07 x | 0.01 x | 0.01 x | 0.01 x |
EV / Revenue | 2.33 x | 1.83 x | 0.94 x | 0.5 x | 0.52 x | 0.52 x | 0.01 x |
EV / EBITDA | - | 55.4 x | 27 x | -5.97 x | -11.4 x | -161 x | 0.3 x |
EV / FCF | - | -26.5 x | -7.85 x | -6.12 x | -9.48 x | -25.9 x | -13.9 x |
FCF Yield | - | -3.77% | -12.7% | -16.4% | -10.6% | -3.86% | -7.17% |
Price to Book | - | 1.33 x | 0.66 x | 0.91 x | -0.2 x | -0.12 x | - |
Nbr of stocks (in thousands) | 599 | 2,902 | 3,697 | 3,745 | 3,803 | - | - |
Reference price 2 | 468.0 | 230.4 | 109.5 | 14.95 | 3.300 | 3.300 | 3.300 |
Announcement Date | 3/8/21 | 3/8/22 | 3/9/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | 120.4 | 403.3 | 631.1 | 751.1 | 849.4 | 1,083 | 1,125 |
EBITDA 1 | - | 13.32 | 22 | -63.05 | -38.48 | -3.52 | 42.1 |
EBIT 1 | - | -4.262 | 0.315 | -90.84 | -77.45 | -38.64 | -7 |
Operating Margin | - | -1.06% | 0.05% | -12.09% | -9.12% | -3.57% | -0.62% |
Earnings before Tax (EBT) 1 | - | -6.516 | -57.34 | -684.2 | -163.3 | -118.2 | -72.8 |
Net income 1 | 7.601 | -6.675 | -37.8 | -683.3 | -145.1 | -111.9 | - |
Net margin | 6.31% | -1.66% | -5.99% | -90.98% | -17.09% | -10.34% | - |
EPS 2 | - | -3.900 | -12.60 | -183.3 | -30.35 | -19.58 | -11.03 |
Free Cash Flow 1 | - | -27.85 | -75.67 | -61.52 | -46.25 | -21.95 | -0.9 |
FCF margin | - | -6.91% | -11.99% | -8.19% | -5.44% | -2.03% | -0.08% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - | - |
Announcement Date | 3/8/21 | 3/8/22 | 3/9/23 | 3/18/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | 104.6 | 118.3 | 136.9 | 172.3 | 157.7 | 164.3 | 173 | 224.4 | 201.8 | 151.8 | 202.1 | 230.6 | 214.2 | 202.5 | 256.6 |
EBITDA 1 | 1.229 | 4.257 | 5.862 | 9.374 | 9.224 | 5.124 | -0.061 | 7.042 | 2.077 | -72.11 | -12.62 | -7.85 | -6.516 | -11.5 | -3.1 |
EBIT 1 | -4.451 | -1.832 | 0.8 | 4.471 | 4.651 | -2.056 | -6.637 | -3.75 | -90.77 | -79.66 | -23.36 | -17.45 | -15.92 | -20.73 | - |
Operating Margin | -4.25% | -1.55% | 0.58% | 2.6% | 2.95% | -1.25% | -3.84% | -1.67% | -44.97% | -52.46% | -11.56% | -7.56% | -7.43% | -10.24% | - |
Earnings before Tax (EBT) 1 | -2.854 | -3.395 | -16.62 | -9.21 | -21.87 | -9.64 | -81.9 | -32.2 | -102.9 | -467.2 | -40.83 | -40.16 | -42.08 | -40.23 | -28.36 |
Net income 1 | -2.854 | -3.553 | -16.8 | -9.381 | -22.05 | 10.43 | -82.08 | -32.38 | -103.1 | -465.8 | -36.31 | -33.97 | -35.25 | -39.61 | -25.64 |
Net margin | -2.73% | -3% | -12.27% | -5.45% | -13.99% | 6.35% | -47.45% | -14.43% | -51.09% | -306.76% | -17.97% | -14.73% | -16.45% | -19.57% | -9.99% |
EPS 2 | -0.9000 | -1.200 | -5.700 | -3.300 | -7.500 | 3.000 | -22.20 | -8.700 | -27.60 | -181.4 | -8.701 | -8.080 | -8.085 | -7.416 | -5.194 |
Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/8/22 | 5/10/22 | 8/9/22 | 11/9/22 | 3/9/23 | 5/10/23 | 8/9/23 | 11/9/23 | 3/18/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt 1 | - | 69.3 | 189 | 320 | 426 | 556 | - |
Net Cash position 1 | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | 5.204 x | 8.607 x | -5.08 x | -11.06 x | -157.9 x | - |
Free Cash Flow 1 | - | -27.8 | -75.7 | -61.5 | -46.2 | -22 | -0.9 |
ROE (net income / shareholders' equity) | - | -3.85% | -2.41% | -36.8% | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share 2 | - | 174.0 | 167.0 | 16.40 | -16.40 | -27.90 | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | 3.99 | 7.45 | 14.6 | 10.5 | 10.8 | 11.3 |
Capex / Sales | - | 0.99% | 1.18% | 1.95% | 1.23% | 1% | 1% |
Announcement Date | 3/8/21 | 3/8/22 | 3/9/23 | 3/18/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-77.92% | 12.55M | |
-14.58% | 85.02B | |
+15.05% | 82.37B | |
+10.49% | 29.29B | |
-10.17% | 17.21B | |
-1.39% | 16.7B | |
-31.40% | 11.8B | |
+1.82% | 12.15B | |
+31.86% | 12.12B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- CMAX Stock
- Financials CareMax, Inc.